Altered expression of caspases-4 and -5 during inflammatory bowel disease and colorectal cancer: Diagnostic and therapeutic potential

Clinical and Experimental Immunology

Volumn 181, Issue 1, 2015, Pages 39-50

  Flood, B ^a   Oficjalska, K ^a   Laukens, D ^b   Fay, J ^c   O'Grady, A ^c   Caiazza, F ^d   Heetun, Z ^d   Mills, K H G ^a   Sheahan, K ^d   Ryan, E J ^d   Doherty, G A ^d   Kay, E ^c   Creagh, E M ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b GHENT UNIVERSITY   (Belgium)

^c BEAUMONT HOSPITAL   (Ireland)

^d ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Caspases; Colorectal cancer; Inflammation; Inflammatory bowel disease

Indexed keywords

BIOLOGICAL MARKER; CASPASE 4; CASPASE 5; INTERLEUKIN 1BETA CONVERTING ENZYME; CASP4 PROTEIN, HUMAN; CASP5 PROTEIN, HUMAN; CASPASE; INITIATOR CASPASE;

ADULT; ARTICLE; CANCER RISK; COLON ADENOCARCINOMA; COLON BIOPSY; COLORECTAL CANCER; DISEASE ACTIVITY; ENTERITIS; FEMALE; HEMICOLECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASE; INTESTINE EPITHELIUM CELL; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM ANTERIOR RESECTION; ULCERATIVE COLITIS; AGED; BIOSYNTHESIS; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CYTOLOGY; EPITHELIUM CELL; INFLAMMATION; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADULT; AGED; BIOMARKERS; CASPASES; CASPASES, INITIATOR; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; EPITHELIAL CELLS; FEMALE; HUMANS; INFLAMMATION; INTESTINAL MUCOSA; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84930678168     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12617     Document Type: Article

References (45)

1. Baumgart DC, Bernstein CN, Abbas Z et al. IBD around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010-Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis 2011; 17:639-44.
2. Molodecky NA, Soon IS, Rabi DM et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142:46-54.
3. Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol 2012; 18:3839-48.
4. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48:526-35.
5. Rubin DT, Huo D, Kinnucan JA et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol 2013; 11:1601-8.e1-4.
6. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
7. Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol 2008; 14:378-89.
8. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010; 138:2101-14.e5.
9. Nicholson DW. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 1999; 6:1028-42.
10. Creagh EM. Caspase crosstalk: integration of apoptotic and innate immune signalling pathways. Trends Immunol 2014; 35:631-40.
11. Mahida YR, Wu K, Jewell DP. Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut 1989; 30:835-8.
12. Pizarro TT, Michie MH, Bentz M et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol 1999; 162:6829-35.
13. Apte RN, Krelin Y, Song X et al. Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur J Cancer 2006; 42:751-9.
14. Vidal-Vanaclocha F, Fantuzzi G, Mendoza L et al. IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci USA 2000; 97:734-9.
15. Becker C, Watson AJ, Neurath MF. Complex roles of caspases in the pathogenesis of inflammatory bowel disease. Gastroenterology 2013; 144:283-93.
16. Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 2007; 14:10-22.
17. Sollberger G, Strittmatter GE, Kistowska M, French LE, Beer HD. Caspase-4 is required for activation of inflammasomes. J Immunol 2012; 188:1992-2000.
18. Kajiwara Y, Schiff T, Voloudakis G et al. A critical role for human caspase-4 in endotoxin sensitivity. J Immunol 2014; 193:335-43.
19. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10:417-26.
20. Soung YH, Jeong EG, Ahn CH et al. Mutational analysis of caspase 1, 4, and 5 genes in common human cancers. Hum Pathol 2008; 39:895-900.
21. Kim YR, Kim KM, Yoo NJ, Lee SH. Mutational analysis of CASP1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 14 genes in gastrointestinal stromal tumors. Hum Pathol 2009; 40:868-71.
22. Schwartz S, Jr, Yamamoto H, Navarro M, Maestro M, Reventos J, Perucho M. Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res 1999; 59:2995-3002.
23. Futreal PA, Coin L, Marshall M et al. A census of human cancer genes. Nat Rev Cancer 2004; 4:177-83.
24. Kayagaki N, Warming S, Lamkanfi M et al. Non-canonical inflammasome activation targets caspase-11. Nature 2011; 479:117-21.
25. Rathinam VA, Vanaja SK, Waggoner L et al. TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by Gram-negative bacteria. Cell 2012; 150:606-19.
26. Wang S, Miura M, Jung YK, Zhu H, Li E, Yuan J. Murine caspase-11, an ICE-interacting protease, is essential for the activation of ICE. Cell 1998; 92:501-9.
27. Barrett JC, Hansoul S, Nicolae DL et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40:955-62.
28. Vandesompele J, De Preter K, Pattyn F et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: 0034.1-11.
29. Bernstein CN, Weinstein WM, Levine DS, Shanahan F. Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol 1995; 90:2106-14.
30. Simpson JL, Phipps S, Baines KJ, Oreo KM, Gunawardhana L, Gibson PG. Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. Eur Respir J 2014; 43:1067-76.
31. Huang TT, Lai HC, Chen YB et al. Cis-resveratrol produces anti-inflammatory effects by inhibiting canonical and non-canonical inflammasomes in macrophages. Innate Immun 2013; 20:735-50. [CrossRef]
32. Oficjalska K, Raverdeau M, Aviello G et al. Protective role for caspase-11 during acute experimental murine colitis. J Immunol 2015; 194:1252-60.
33. Demon D, Kuchmiy A, Fossoul A, Zhu Q, Kanneganti TD, Lamkanfi M. Caspase-11 is expressed in the colonic mucosa and protects against dextran sodium sulfate-induced colitis. Mucosal Immunol 2014; 7:1480-91.
34. Lin XY, Choi MS, Porter AG. Expression analysis of the human caspase-1 subfamily reveals specific regulation of the CASP5 gene by lipopolysaccharide and interferon-gamma. J Biol Chem 2000; 275:39920-6.
35. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006; 4:221-33.
36. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004; 202:275-93.
37. Rohban R, Reinisch A, Etchart N et al. Identification of an effective early signaling signature during neo-vasculogenesis in vivo by ex vivo proteomic profiling. PLOS ONE 2013; 8:e66909.
38. Mathonnet M, Perraud A, Christou N et al. Hallmarks in colorectal cancer: angiogenesis and cancer stem-like cells. World J Gastroenterol 2014; 20:4189-96.
39. Greten FR, Eckmann L, Greten TF et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118:285-96.
40. Lakshmanan U, Porter AG. Caspase-4 interacts with TNF receptor-associated factor 6 and mediates lipopolysaccharide-induced NF-kappaB-dependent production of IL-8 and CC chemokine ligand 4 (macrophage-inflammatory protein-1). J Immunol 2007; 179:8480-90.
41. Ullman T, Odze R, Farraye FA. Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon. Inflamm Bowel Dis 2009; 15:630-8.
42. Melville DM, Jass JR, Morson BC et al. Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. Hum Pathol 1989; 20:1008-14. [CrossRef]
43. Lim CH, Dixon MF, Vail A, Forman D, Lynch DA, Axon AT. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut 2003; 52:1127-32.
44. Harpaz N, Talbot IC. Colorectal cancer in idiopathic inflammatory bowel disease. Semin Diagn Pathol 1996; 13:339-57.
45. Ullman T, Croog V, Harpaz N, Sachar D, Itzkowitz S. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003; 125:1311-9.